LEAP THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.845 USD | -3.89% |
|
-11.19% | -30.58% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 25.86M | Capitalization | 75.79M |
|---|---|---|---|---|---|
| Net income 2024 * | -69M | Net income 2025 * | -69M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.93 x |
| P/E ratio 2024 * |
-1.31
x | P/E ratio 2025 * |
-1.99
x | Employees | 54 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Leap Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -1.33% | ||
| 1 week | -4.98% | ||
| Current month | +11.28% | ||
| 1 month | +38.32% | ||
| 3 months | -7.50% | ||
| 6 months | +92.21% | ||
| Current year | -28.59% |
1 week
2.75
3.49
1 month
2.214.39
Current year
2.135.00
1 year
1.2410.20
3 years
1.2441.70
5 years
1.2441.70
10 years
1.24102.50
| Managers | Title | Age | Since |
|---|---|---|---|
Doug Onsi
CEO | Chief Executive Officer | 55 | 10-12-31 |
Chris Mirabelli
CHM | Chairman | 69 | 10-12-31 |
Jason Baum
CTO | Chief Tech/Sci/R&D Officer | 45 | 20-08-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joseph Loscalzo
BRD | Director/Board Member | 72 | 15-12-31 |
Nissim Mashiach
BRD | Director/Board Member | 63 | 16-12-31 |
Chris Mirabelli
CHM | Chairman | 69 | 10-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 2.878 | -2.78% | 66 863 |
| 24-04-18 | 2.96 | -1.33% | 101,762 |
| 24-04-17 | 3 | +0.67% | 146,417 |
| 24-04-16 | 2.98 | -0.67% | 151,233 |
| 24-04-15 | 3 | -7.41% | 521,740 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.96
USD
Average target price
11.75
USD
Spread / Average Target
+296.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.59% | 75.79M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.89% | 21.66B | |
| -18.35% | 20.77B | |
| -8.93% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- LPTX Stock
